Form 4: Charlotte A. Swafford Reports Stock Option Grant and Beneficial Ownership in National Health Investors Inc.
SEC Form 4 Filing
Director Charlotte A. Swafford reports acquisition of stock options and updates to beneficial ownership in National Health Investors Inc.
Summary
- On March 3, 2025, Charlotte A. Swafford, a director of National Health Investors Inc. (NHI), reported a transaction involving derivative securities.
- Swafford acquired 10,000 stock options with an exercise price of $73.34, exercisable from March 3, 2025, and expiring on March 3, 2030.
- The report also details Swafford's direct ownership of several other stock option grants from 2021 to 2024, as well as indirect ownership of 110,185 common stock shares held in a trust.
- The filing was signed on March 5, 2025, by Kimberly V. Ouimet under a limited power of attorney.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the healthcare REIT industry where National Health Investors operates. It reflects standard practices for incentivizing and aligning the interests of directors with the company's performance.
Comparison to Industry Standards
- Stock option grants are a common component of executive compensation packages in the REIT sector, including companies like Welltower (WELL), Ventas (VTR), and Healthpeak Properties (PEAK).
- The size and terms of the option grants are generally aligned with industry benchmarks for companies of similar size and market capitalization.
- Comparing the exercise price and vesting schedules with those of peer companies would provide a more detailed assessment of the competitiveness of NHI's executive compensation.
Stakeholder Impact
- The granting of stock options can potentially align the interests of the director with those of the shareholders, encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/25/2021 | Date of Stock Options (Right to Buy) grant with exercise price of $69.2 and expiration date of 02/25/2026 for 25,000 shares. |
| 02/25/2022 | Date of Stock Options (Right to buy) grant with exercise price of $53.41 and expiration date of 02/25/2027 for 25,000 shares. |
| 02/24/2023 | Date of Stock Options (Right to Buy) grant with exercise price of $54.73 and expiration date of 02/24/2028 for 10,000 shares. |
| 02/23/2024 | Date of Stock Options (Right to Buy) grant with exercise price of $57.76 and expiration date of 02/23/2029 for 10,000 shares. |
| 03/03/2025 | Date of the reported transaction: acquisition of 10,000 stock options at $73.34, exercisable from 03/03/2025 and expiring on 03/03/2030. |
| 03/05/2025 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.